US government health officials approved the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings fromindependent advisers that the much debated treatment hasn’t vbeen shown to help slow the brain destroying disease.
ThevFood and Drug Administration said it granted approval to the drug development by Biogen for patients with Alzheimer’s disease.
it’s the only drug that US regulators have said can likely treat the underlying disease, rather than manage symptoms like anxiety and insomnia.
The decision, which could impact millions of around the world, is certain to spark disagreements among physicians, medical researchers and patient groups. It also has far reaching implications for the standards used to evaluate experimental therapies, including those that show only incremental benefits.
The new drug, which Biogen developed with Japan’s Eisai Co., did not reverse mental decline, only showing it in one study. Named Aduhelm, the medication is given as an infusion every for weeks